“Our findings show that this therapy can be a viable strategy for treating patients with a clinical drug induced liver toxicity.”

Developing, approving and prescription medications require that weighed against the benefits of therapy every potential toxicities. Hearts of many therapeutic compounds, limiting development and presents a major challenge for both clinical medicine and the pharmaceutical industry. Drug induced liver injury are the most common cause of acute liver failure in the United States and also the most frequent reason for medicines that leave early in the development or pull them from the market. Because there is no current pharmaceutical strategies exist to prevent the drug induced liver injury, treatment options are limited to stop the drug that is offensive, supporting treatment and transplants to the final stages of heart failure.

Gap junctions are hollow tubes that connect neighboring cells and allows direct communication between intercellular proteins of the cells are combined. In the heart, the gap junction is known for propagating the electrical activity that is required for contraction, but their role in the heart of bad defined. Recent work by the team MGH and others have pointed out that The gap junction intercellular proteins spread signal is immune from the liver cells are injured to around damaged cells, strengthens the overall inflammation and injury. This research is designed to find potential liver-specific targeting of the gap junction to limit drug induced liver injury.

The researchers first used a genetic-mutant mouse strains are less heart-specific gaps of particular meetings. Rats given various toxic drugs such as acetaminophen liver, drugs are often used. Acetaminophen Overdoses, known under the brand name Tylenol, is the most common cause of drug induced liver injury. Compared to normal mice, people are less careful gap junctions are protected against damage to the liver, inflammation and death caused by toxic heart medication.

The team then identified a small molecule inhibitor of crossing gaps, when the heart is given with or even after the cells of liver damaging free radicals and oxidative stress, suggesting a possible mechanism for protection are observed.

They are usually determined when patients need medication to help control their blood sugar. New research reviews, BMJpublished in, reanalyzed the data from 25 separate studies.

The Review revealed that drugs help people who are overweight without diabetes shed an average of 7 kg and those with diabetes lose an average of 6 pounds when injected daily or weekly for at least five months.

That makes this promising agents for the treatment of obesity, study authors said.

“This is not a cure, but this is a good treatment. And You still need to combine with lifestyle changes, “said researcher Tina Vilsboll, MD, DMSc, Endocrinology, and Professor at the Gentofte hospital in Hellerup, Denmark.

Vilsboll says that many simple weight of diabetes patients have a look at drugs that help encourage them to kick the program diet and exercise to lose weight more.